Mannosulfan

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 73.147.9.33 (talk) at 14:10, 24 July 2019. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Mannosulfan
Clinical data
Other names[(2R,3S,4S,5R)-3,4-dihydroxy-2,5,6-tris(methylsulfonyloxy)hexyl] methanesulfonate
ATC code
Identifiers
  • 1,2,5,6-Tetrakis-O-(methylsulfonyl)-D-mannitol
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC10H22O14S4
Molar mass494.53 g/mol g·mol−1
3D model (JSmol)
  • CS(=O)(=O)OC[C@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)C)OS(=O)(=O)C)O)O)OS(=O)(=O)C
  • InChI=1S/C10H22O14S4/c1-25(13,14)21-5-7(23-27(3,17)18)9(11)10(12)8(24-28(4,19)20)6-22-26(2,15)16/h7-12H,5-6H2,1-4H3/t7-,8-,9-,10-/m1/s1
  • Key:UUVIQYKKKBJYJT-ZYUZMQFOSA-N
  (verify)

Mannosulfan (INN) is an alkylating agent with the potential for the treatment of cancer. It is not approved by the United States FDA for cancer treatment. Research suggests it is less toxic than the alkyl sulfonate Busulfan.[1]

References

  1. ^ Jeswani, Gunjan; Paul, Swarnali D (2017). "Recent Advances in the Delivery of Chemotherapeutic Agents". Nano- and Microscale Drug Delivery Systems. pp. 281–98. doi:10.1016/B978-0-323-52727-9.00015-7. ISBN 978-0-323-52727-9.

External links